Sarcomatoid
A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS)
The American Journal of Surgical Pathology 2021 December 15 [Link] Talia L Fuchs, Angela Chou, Yagiz Aksoy, Mahiar Mahjoub, Amy Sheen, Loretta Sioson, Mahsa Ahadi, Anthony J Gill Abstract Although there is early support for schemes based on nuclear grade, necrosis and mitotic rate, there is currently no widely implemented grading system for diffuse pleural…
Read MoreJME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Journal for Immunotherapy of Cancer 2021 October [Link] Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto Abstract Background: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). Patients and methods:…
Read MoreThoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas
Thoracic Cancer 2021 October 15 [Link] Kanji Otsubo, Hiroki Sakai, Hiroyuki Kimura, Tomoyuki Miyazawa, Hideki Marushima, Koji Kojima, Naoki Furuya, Masamichi Mineshita, Motohiro Chosokabe, Junki Koike, Hisashi Saji Abstract Background: The current study aimed to evaluate the significance of clinicopathological factors, particularly the immunohistochemistry of programed cell death ligand-1 (PD-L1), in eight cases each of…
Read MoreA Novel Therapeutic Strategy Targeting the Mesenchymal Phenotype of Malignant Pleural Mesothelioma By Suppressing LSD1
Molecular Cancer Research 2021 September 30 [Link] Aditya Wirawan, Ken Tajima, Fumiyuki Takahashi, Yoichiro Mitsuishi, Wira Winardi, Moulid Hidayat, Daisuke Hayakawa, Naohisa Matsumoto, Kenta Izumi, Tetsuhiko Asao, Ryo Ko, Naoko Shimada, Kazuya Takamochi, Kenji Suzuki, Masaaki Abe, Okio Hino, Yoshitaka Sekido, Kazuhisa Takahashi Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that has…
Read MoreMolecular characterization of pleomorphic mesothelioma: a multi-institutional study
Modern Pathology 2021 September 16 [Link] Somak Roy, Françoise Galateau-Sallé, Nolwenn Le Stang, Andrew Churg, Maureen A Lyons, Richard Attanoos, Sanja Dacic Abstract The molecular alterations of pleomorphic mesotheliomas are largely unknown. In the present study, we performed whole-exome sequencing (WES) on 24 pleomorphic mesotheliomas in order to better characterize the molecular profile of this…
Read MoreMalignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes
Abdominal Radiology 2021 August 3 [Link] Isha D Atre, Gaurav V Watane, Mukesh G Harisinghani Abstract Purpose: To identify correlation between CT imaging features and histologic subtypes of Malignant Peritoneal Mesothelioma (MPM). Methods: This was a retrospective single-center study of 51 consecutive patients with the diagnosis of Malignant Peritoneal Mesothelioma (MPM). The tumors were classified…
Read MoreSignificance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status
Modern Pathology 2021 September 8 [Link] Julia R Naso, Basile Tessier-Cloutier, Janine Senz, David G Huntsman, Andrew Churg Abstract p53 immunohistochemistry has long been proposed for the separation of benign from malignant mesothelial proliferations, with the older literature suggesting that any degree of positivity supported a diagnosis of mesothelioma. However, using modern immunohistochemistry platforms in…
Read MoreLoss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
American Journal of Clinical Pathology 2021 August 31 [Link] Simone Terra, Anja C Roden 1, Eunhee S Yi, Marie Christine Aubry, Jennifer M Boland Abstract Objectives: Differentiating malignant pleural mesothelioma from benign reactive mesothelial processes can be quite challenging. Ancillary tests such as BRCA1-associated protein 1 (BAP1) immunohistochemistry and p16 fluorescence in situ hybridization (FISH)…
Read MoreMalignant pleural mesothelioma with heterologous elements
Journal of Clinical Pathology 2021 August 10 [Link] Toshiaki Kawai, Reishi Seki, Kuniharu Miyajima, Hiroshi Nakashima, Takayuki Takeda, Tomoyuki Murakami, Keisuke Aoe, Kazunori Okabe, Keiichi Homma, Yoshitane Tsukamoto, Koichi Sunada, Yasuhiro Terasaki, Maki Iida, Hideki Orikasa, Kenzo Hiroshima Abstract Aims: Malignant pleural mesothelioma with heterologous elements (such as osseous, cartilaginous or rhabdomyoblastic differentiation) is very…
Read MoreMalignant pleural mesothelioma with heterologous elements
Journal of Clinical Pathology 2021 August 10 [Link] Toshiaki Kawai, Reishi Seki, Kuniharu Miyajima, Hiroshi Nakashima, Takayuki Takeda, Tomoyuki Murakami, Keisuke Aoe, Kazunori Okabe, Keiichi Homma, Yoshitane Tsukamoto, Koichi Sunada, Yasuhiro Terasaki, Maki Iida, Hideki Orikasa, Kenzo Hiroshima Abstract Aims: Malignant pleural mesothelioma with heterologous elements (such as osseous, cartilaginous or rhabdomyoblastic differentiation) is very…
Read More